Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mecasermin rinfabate - Oak Hill Bio/ Takeda

X
Drug Profile

Mecasermin rinfabate - Oak Hill Bio/ Takeda

Alternative Names: HGT-ROP-001; IGF-I/IGFBP-3; Insulin-like growth factor-I/insulin-like growth factor binding protein-3; IPLEX; Mecasermin rinfabate; OHB-607; Premiplex; rhIGF-I/rhIGFBP-3; SHP607; SomatoKine; Somatomedin-C/Somatomedin-1-binding-protein-3; TAK 607

Latest Information Update: 11 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insmed
  • Developer Insmed; Oak Hill Bio; Takeda
  • Class Antihyperglycaemics; Eye disorder therapies; Growth factors; Osteoporosis therapies; Recombinant proteins
  • Mechanism of Action Insulin like growth factor binding protein 3 stimulants; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Insulin resistance; Muscular dystrophies; Growth disorders; Retinopathy of prematurity
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchopulmonary dysplasia; Lung disorders
  • Market Withdrawal Growth disorders
  • Suspended Muscular dystrophies
  • No development reported Amyotrophic lateral sclerosis; Retinopathy of prematurity
  • Discontinued Burns; Fracture; Insulin resistance; Lipodystrophy; Postmenopausal osteoporosis; Short stature; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 10 Jan 2024 Chiesi Group entered into research and development agreement with Oak Hill for the development of OHB-607
  • 09 Jan 2024 Chiesi Group and Oak Hillplans plans to re-initiate phase IIb trial for Bronchopulmonary dysplasia in the United States, Europe, and Japan in 2024
  • 25 May 2022 Oak Hill Bio plans a phase IIb study of Mecasermin rinfabate in year 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top